2015 American Transplant Congress
Pharmacokinetics of Everolimus (EVL) in Elderly Recipients Under Low-Tacrolimus(TAC)/Everolimus in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly ( >60 years) recipients are being renal transplanted more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include…2015 American Transplant Congress
Mycophenolate Dose Reductions Contribute to Suboptimal Graft Outcomes in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC.
The purpose of this study was to analyze outcomes in patients with mycophenolate mofetil (MMF) dose reductions below doses proven to prevent rejection in a…2015 American Transplant Congress
In Vivo Expansion of Donor-Specific Regulatory T Cells by a New Triazolopyrimidine Derivative and Donor-Specific Transfusion
Background: We have previously demonstrated that a new triazolopyrimidine derivative, NK026680 (NK) prevents activation/maturation of dendritic cells. This study investigated whether NK together with donor-specific…2015 American Transplant Congress
TIM-4 Identifies IL-17 Expressing Pro-Inflammatory Be-17 Cells That Promote Allograft Rejection
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.
We identified TIM-1 as an inclusive marker for IL-10+ regulatory B cells (TIM-1+ Bregs), which prolong islet allograft survival (GS). We recently found that TIM-4,…2015 American Transplant Congress
Everolimus Initiation Immediately After Liver Transplantation: A Single-Center Experience
University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
BackgroundClinical trials in liver transplant (LTX) patients with randomization on day 30 to everolimus (EVR) show a benefit in renal function compared to calcineurin inhibitor…2015 American Transplant Congress
De Novo Donor-Specific HLA Antibodies After Kidney Transplantation Are Associated With Donation After Circulatory Death and HLA-DQ Mismatch
Introduction: De novo donor-specific HLA-antibodies (dnDSA) have been associated with rejection and inferior kidney graft survival. The purpose of this study was to investigate the…2015 American Transplant Congress
Neurocognitive Profile of Children Born to Kidney Transplant Recipients Mothers
Aim. To compare neurocognitive abilities of children of kidney transplant (KT) recipients who were exposed to immunosuppression during pregnancy with unexposed children. Methods. In this…2015 American Transplant Congress
Chimerism for Early Detection of Graft Versus Host Disease in Intestinal Transplantation
Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, FL.
Graft versus host disease (GVHD) is a potentially fatal complication after multivisceral transplantation (MVT). By definition, donor cells must be present in the blood of…2015 American Transplant Congress
Lipid Profiles Over 2 Years Follow-Up in De Novo Kidney Transplant Recipients Randomized to Once-Daily MeltDose® Tacrolimus (Envarsus® XR) Vs. Twice-Daily Tacrolimus (Prograf®): Results from a Phase 3, Double-Blind, Double-Dummy, Multicenter Trial
Cardiovascular disease (CVD) is a leading cause of death in kidney transplant recipients (KTR). Focusing on modifiable CVD risk factors is key to decreasing CVD-related…2015 American Transplant Congress
Combined Anti-IL6R and CTLA4Ig Therapy Attenuates Recall Alloantibody Responses in a Mouse Model of HLA Sensitization
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
[bald]Background[/bald] We previously reported that IL-6 inhibition by anti-IL6R antibody (mMR16-1) or CD28 pathway inhibition using CTLA4Ig (abatacept) reduced recall alloantibody responses in a mouse…
- « Previous Page
- 1
- …
- 129
- 130
- 131
- 132
- 133
- …
- 138
- Next Page »